Home/Filings/4/0000950170-24-067360
4//SEC Filing

Simson Jake 4

Accession 0000950170-24-067360

CIK 0001863127other

Filed

May 30, 8:00 PM ET

Accepted

May 31, 4:30 PM ET

Size

6.3 KB

Accession

0000950170-24-067360

Insider Transaction Report

Form 4
Period: 2024-05-29
Simson Jake
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-05-29+18,60018,600 total
    Exercise: $15.94Exp: 2034-05-28Common Stock (18,600 underlying)
Footnotes (2)
  • [F1]The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
  • [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Documents

1 file

Issuer

Tyra Biosciences, Inc.

CIK 0001863127

Entity typeother

Related Parties

1
  • filerCIK 0001863094

Filing Metadata

Form type
4
Filed
May 30, 8:00 PM ET
Accepted
May 31, 4:30 PM ET
Size
6.3 KB